Perhaps the most striking recent improvements in lung cancer survival are seen among patients whose cancers are driven by a distinctive molecular event, the fusion between echinoderm microtubule‐associated protein‐like 4 (EML4) and anaplastic lymphoma kinase (ALK). This evidence concerns the gene ALK and lung cancer.